ArticleJournal of asthma and allergy2026
Real-World Comparative Effectiveness of Mepolizumab versus Benralizumab in an Older Population with Asthma: A US Medicare Fee-for-Service Analysis.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biologic therapies, including mepolizumab and benralizumab, are used to treat uncontrolled asthma. However, real-world evidence comparing these treatments is limited. This study compared asthma-related hospitalizations and asthma exacerbations between mepolizumab and benralizumab among Medicare fee-for-service (FFS) beneficiaries with asthma. Methods: Data were obtained from Komodo Research Database (01/01/2018-05/31/2025). Eligible patients included Medicare FFS beneficiaries with asthma and a first claim for mepolizumab or benralizumab on or after January 1, 2019 (index date). An adherent subgroup included those who remained adherent to their index biologic for ≥6 months. Overlap weighting based on a propensity score model was used to balance cohorts. Asthma-related hospitalizations and asthma exacerbations were evaluated while on treatment. Rates were reported as the number of events per-patient-year (PPY) and compared between weighted cohorts using rate ratios (RRs) with 95% confidence intervals (CIs). Non-inferiority using a fixed-margin approach was used to compare rates of asthma-related hospitalizations between cohorts. Results: In total, 125 and 177 patients were included in the mepolizumab and benralizumab cohorts, respectively (mean age: 70.7 years, 69.1 years). After weighting, baseline characteristics were well-balanced. At 1-year post-index, mepolizumab demonstrated superiority over benralizumab for asthma-related hospitalizations, showing a 77% rate reduction (0.036 PPY vs 0.155 PPY; RR: 0.23, 95% CI: 0.07, 0.74; p=0.013) and was associated with comparable rates of asthma exacerbations (1.056 PPY vs 1.302 PPY; RR: 0.81, 95% CI: 0.52, 1.26; p=0.348). In the adherent subgroup, mepolizumab remained superior to benralizumab for asthma-related hospitalizations (0.040 PPY vs 0.167 PPY; RR: 0.24, 95% CI: 0.07, 0.79; p=0.019) and remained associated with comparable rates of asthma exacerbations (0.927 PPY vs 1.249 PPY; RR: 0.74, 95% CI: 0.44, 1.25; p=0.265). Consistent results were observed at 2-years post-index. Conclusion: Mepolizumab was superior to benralizumab for asthma-related hospitalizations, while asthma exacerbation rates were comparable between the two therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.